Navigation Links
Australian Therapeutics Goods Administration Approval for ActiPatch Achieved
Date:10/9/2007

FREDERICK, Md., Oct. 9 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (Pink Sheets: BIEL), announced today that the Australian Therapeutic Goods Administration has cleared ActiPatch for sale by its distributor, Endotherapeutics Party Limited.

"We are confident that the experienced sales professionals of Endotherapeutics will successfully launch ActiPatch in the Australian market. Endotherapeutics' team has many decades of experience in the medical devices market and their people come from well known established medical devices companies," said Andrew Whelan, President of BioElectronics Corporation.

Ivan Srejber, Managing Director of Endotherapeutics Party Limited, said "We have extensive experience in launching products and establishing significant market share for previously unknown products. We are very excited about the market potential for ActiPatch in Australia and look forward to a mutually beneficial business partnership with BioElectronics Corporation."

About Endotherapeutics Party Limited:

Founded in 1998, Endotherapeutics has provided medical technologies for the health care specialist throughout Australia. Companies represented by Endotherapeutics are leaders in their specific market segments. To learn more about Endotherapeutics Party Limited please visit http://www.endotherapeutics.com.au.

About BioElectronics:

BioElectronics Corporation is the maker of ActiPatch. ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective, patient friendly method to reduce soft tissue pain and swelling.

For more information visit http://www.bioelectronicscorp.com

Safe Harbor Statement:

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.


'/>"/>
SOURCE BioElectronics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Imago provides atomic probe to Australian lab
2. Australian company will sell TeraMedicas medical imaging software
3. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
4. Third Wave seeks approval of Cystic Fibrosis test
5. Kyron wins FDA approval for brain imaging technology
6. SGI receives court approval for bankruptcy motions
7. FDA programs encourage and expedite drug development and approval
8. UW-Stevens Point Professor Receives Patent Approval For New Technology
9. High-Efficiency Transfections Achieved with New Low-Toxicity Reagent
10. 140-Fold Increase of Protein Achieved in Pichia Fermentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Maine (PRWEB) , ... January 17, 2017 , ... ... the addition of Rheumatoid Factor (RF) to its VALIDATE® SP2 calibration verification / ... Factor in a human serum base. Each VALIDATE® SP2 kit is prepared using ...
(Date:1/17/2017)... 17, 2017  Zimmer Biomet Holdings, Inc. (NYSE and ... 2016 sales and earnings conference call will be broadcast ... at 8 a.m. Eastern Time.  A news release detailing ... at 7:30 a.m. Eastern Time the morning of the ... be accessed via Zimmer Biomet,s Investor Relations website at ...
(Date:1/17/2017)... , Jan. 17, 2017  Northwell Health today ... advance of precision cancer research. ... largest health care provider, Northwell Health diagnoses and ... GmbH is a Germany -based ... therapies. Together they will greatly expand cancer biobanking ...
(Date:1/17/2017)... ... January 17, 2017 , ... Diagenode, a ... announced a collaboration with the Heidelberg University Hospital and the German Cancer Research ... following the company’s successful launch of its CATS (Capture and Amplification by ...
Breaking Biology Technology:
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016 /PRNewswire/ ... que permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado que ... de tumor en 2017, con múltiples sitios previstos a lo largo ... ... en el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que ...
(Date:12/15/2016)... Dec. 15, 2016   WaferGen Bio-systems, Inc. ... technology company, announced today that on December 13, 2016, ... of The Nasdaq Stock Market LLC which acknowledged that, ... of WaferGen,s common stock had been at $1.00 or ... regained compliance with Listing Rule 5550(a)(2) of the Nasdaq ...
(Date:12/12/2016)... 12, 2016  Researchers at Trinity College, Dublin, ... by combining the material with Silly Putty. The mixture ... detector able to sense pulse, blood pressure, respiration, ... The research team,s findings were ... here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):